Itrakan 130 SB Capsule contains Itraconazole 130 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole acts by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase, which is essential for ergosterol synthesis, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrakan 130 SB is effective against infections caused by dermatophytes, yeasts, and molds, including conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and candidiasis. The capsule formulation ensures optimal bioavailability and patient compliance. It is recommended to be administered orally with food to enhance absorption. Dosage and duration depend on the type and severity of infection, and treatment should be guided by a healthcare professional. Caution is advised in patients with hepatic impairment or congestive heart failure. Potential adverse effects include gastrointestinal disturbances, headache, and elevated liver enzymes. Itraconazole has known drug interactions due to its effect on cytochrome P450 enzymes; therefore, concomitant use with certain medications should be carefully monitored. Regular liver function tests and clinical evaluation are recommended during prolonged therapy to ensure safety and efficacy.